What is the 13F Pro Quality Score for SLDB?

13F Pro ranks Solid Biosciences Inc. (SLDB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SLDB's current score at https://13fpro.ai/company/SLDB (free sign-up required for the full ranking).

Where does 13F Pro source SLDB data?

All Solid Biosciences Inc. fundamentals and ownership data come directly from SEC EDGAR. Solid Biosciences Inc. files with the SEC under CIK 1707502. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SLDB in?

Solid Biosciences Inc. (SLDB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SLDB research updated on 13F Pro?

SLDB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Solid Biosciences Inc.(SLDB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1707502 SLDB stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

SLDB Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Solid Biosciences Inc. (SLDB), a Healthcare sector company. SLDB is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Solid Biosciences Inc. reports net income of $-54.8M, free cash flow of $-52.7M. Top institutional holders of SLDB by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS, Bain Capital Life Sciences Investors, based on the most recent SEC filings. SLDB trades on the Nasdaq exchange and files with the SEC under CIK 1707502. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLDB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Solid Biosciences Inc. directly from SEC EDGAR. Solid Biosciences Inc.'s 13F Pro composite quality score has ranged between 24 and 30 since 2023, currently 23.6 — a declining long-term trajectory across 9 quarterly and live scoring snapshots.

✦

Fun facts about Solid Biosciences Inc.

Quirks, history, and lore behind SLDB — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biotech company · listed on Nasdaq · headquartered in Massachusetts · focused on rare and devastating genetic diseases.
2
The Numbers
With no approved products yet, annual revenue is minimal — the company runs on cash runway and the hope that its pipeline pays off before the tank runs dry.
3
The History
Founded in the mid-2010s, it was built around a single urgent mission: developing a gene therapy for one of the most heartbreaking childhood muscle diseases known to medicine.
4
The Secret
Its lead program targets Duchenne muscular dystrophy (DMD) — a progressive, fatal condition caused by mutations in the gene that encodes dystrophin, the largest gene in the human body.
5
The Lore
The company was co-founded with the help of patient families who refused to wait for Big Pharma, embedding a patient-advocacy ethos directly into its founding DNA — literally.
6
The Giveaway
Its ticker spells out its ambition: SLDB — a small but determined crew swinging for a cure for Duchenne, backed by science, grief, and stubbornness in equal measure.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-54.8M

Free Cash Flow

Q2 2026

$-52.7M

ROIC

Q2 2026

-61.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2025

FY22 $8.1MFY23 —FY24 —FY25 —

Operating Income

-38.1% YoY

$-179.2MFY 2025

FY22 $-106.5MFY23 $-104.3MFY24 $-129.7MFY25 $-179.2M

EPS (Diluted)

+35.0% YoY

$-1.99FY 2025

FY22 $-5.05FY23 $-2.42FY24 $-3.06FY25 $-1.99

Total Assets

+23.3% YoY

$232.5MFY 2025

FY22 $260.3MFY23 $164.9MFY24 $188.7MFY25 $232.5M

Op. Cash Flow

-56.3% YoY

$-156.3MFY 2025

FY22 $-98.0MFY23 $-94.2MFY24 $-100.0MFY25 $-156.3M

Free Cash Flow

-56.4% YoY

$-157.4MFY 2025

FY22 $-101.0MFY23 $-95.7MFY24 $-100.7MFY25 $-157.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	—	$8.1M -40.6%	$13.6M	$0.00
Operating Income	$-179.2M -38.1%	$-129.7M -24.4%	$-104.3M +2.1%	$-106.5M -47.3%	$-72.3M +18.3%	$-88.4M
EPS (Diluted)	$-1.99 +35.0%	$-3.06 -26.7%	$-2.42 +52.2%	$-5.05 +0.4%	$-5.07 +80.1%	$-25.50
Total Assets	$232.5M +23.3%	$188.7M +14.4%	$164.9M -36.6%	$260.3M +12.0%	$232.4M +35.8%	$171.2M
Operating Cash Flow	$-156.3M -56.3%	$-100.0M -6.2%	$-94.2M +3.9%	$-98.0M -26.0%	$-77.8M -37.4%	$-56.6M
Free Cash Flow	$-157.4M -56.4%	$-100.7M -5.2%	$-95.7M +5.2%	$-101.0M -27.8%	$-79.0M -37.5%	$-57.5M

Get alerted when SLDB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Solid Biosciences Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SLDB

RA CAPITAL MANAGEMENT, L.P.
$120.2M12,036,126 sh
PERCEPTIVE ADVISORS LLC
$118.9M11,906,646 sh
Bain Capital Life Sciences Investors, LLC
$98.0M9,808,819 sh
Siren, L.L.C.
$76.8M7,690,405 sh
BlackRock, Inc.
$69.3M6,934,248 sh
FMR LLC
$68.7M6,875,957 sh
ARMISTICE CAPITAL, LLC
$42.7M4,278,000 sh
STATE STREET CORP
$41.7M4,175,365 sh
Jupiter Topco LLC
$40.4M4,043,605 sh
VANGUARD CAPITAL MANAGEMENT LLC
$40.1M4,009,922 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$120.2M	12,036,126
PERCEPTIVE ADVISORS LLC	$118.9M	11,906,646
Bain Capital Life Sciences Investors, LLC	$98.0M	9,808,819
Siren, L.L.C.	$76.8M	7,690,405
BlackRock, Inc.	$69.3M	6,934,248
FMR LLC	$68.7M	6,875,957
ARMISTICE CAPITAL, LLC	$42.7M	4,278,000
STATE STREET CORP	$41.7M	4,175,365
Jupiter Topco LLC	$40.4M	4,043,605
VANGUARD CAPITAL MANAGEMENT LLC	$40.1M	4,009,922

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SLDB on your watchlist

Track score changes the day Solid Biosciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SLDB a good stock to buy?

13F Pro's AI-powered analysis of Solid Biosciences Inc. (SLDB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SLDB are available on the SLDB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SLDB is classified as a small company.

Which hedge funds own SLDB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SLDB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Solid Biosciences Inc.'s investment landscape.